Synimmune Equity Ltd was incorporated in 2010 in Vaduz, Lichtenstein. Its subsidiary Synimmune GmbH is based in Tübingen, Germany, and was incorporated in 2010.

Synimmune GmbH is a spin-off of the Department of Immunology of the University of Tübingen, which was from 2012 to 2016 initially supported by the GO-Bio programme of the German Ministry of Education and Research ("BMBF").

Synimmune GmbH is a biotechnology company dedicated to the development of innovative and effective mono-and bispecific anti-tumour antibodies for the treatment of patients suffering from life-threatening diseases.

Synimmune focuses on orphan hematopoietic malignancies. It aims to accelerate the passage of new anti-cancer drugs from laboratory to clinic.

Synimmune GmbH is currently focusing on two projects implemented together with KfW (Kreditanstalt fürWiederaufbau) A.d.ö.R. (Frankfurt, Germany) as shareholder and co-investor in the framework of the programme

ERP-Startfonds.

One of the projects uses the monospecific antibody FLYSYN for the treatment of acute myeloidleukaemia ("AML") on patients at a stage of minimum residual disease ("MRD"). The effectiveness andcompatibility of the antibody has already been proven in first treatment attempts. The company is currentlypreparing for a Phase II clinical study to further demonstrate efficacy of the antibody. The company initially triedto combine Phase I with Phase IIa, which led to mixed results not ready for use. As a result, the company decidedto carry out a Phase II study, which is currently ongoing. The other project is a FLT3xCD3 bispecific antibody ("TACSYN") for the therapy of AML and acutelymphoblastic leukaemia (“ALL”) in patients whose disease is characterised by a relatively high and growingnumber of tumour cells. The project is based on bispecific antibodies for the therapy of antitumor immunology.Synimmune GmbH has completed the preclinical characterisation of TACSYN with high target specificity. In addition, Synimmune has developed a GMP (Good Manufacturing Practice) manufacturing process for TACSYN.

‍

For more information, please visit: www.synimmune.de

‍